查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1857733

人源化小鼠和大鼠模型市場（按模型類型、應用、最終用戶和產品類型分類）—2025-2032年全球預測

Humanized Mouse & Rat Model Market by Model Type, Application, End User, Product Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人源化小鼠和大鼠模型市場將成長至 4.9448 億美元，複合年成長率為 7.56%。

關鍵市場統計數據
基準年 2024 2.7591億美元
預計年份：2025年 2.9724億美元
預測年份 2032 4.9448億美元
複合年成長率 (%) 7.56%

專家概述了人源化小鼠和大鼠模型的創新如何重塑前臨床開發平臺和轉化研究重點。

人源化小鼠和大鼠模型已成為現代臨床前研究的重要工具，為免疫學、感染疾病、腫瘤學、神經病學和心血管科學等領域的轉化研究提供了重要依據。這些人工建構的、源自患者的模型系統，透過提供生理相關的環境，日益彌合了體外研究結果與臨床現實之間的差距，使研究人員能夠深入探討人類特異性的免疫相互作用、病原體趨向性和腫瘤生物學特性。隨著實驗目標的日益複雜，研究人員和產品開發人員正在尋求更逼真的模型、更可靠的表徵方法以及能夠加快獲得可操作資料速度並提高實驗可重複性的綜合服務。

因此，供應商、合約研究機構和學術聯盟已擴展其產品組合，納入高度人源化的大鼠變體、更廣泛的免疫力缺乏品系、患者來源的異質骨移植模型庫以及精準的基因改造構建體。同時，基因組編輯、育種和飼養技術的進步，以及表現型分析和生物檢測能力的增強，重塑了申辦者設計臨床前計畫的方式。本導言重點闡述了當前情勢下營運的複雜性和科學機遇，並為深入分析影響模型選擇、籌資策略、監管環境和最終用戶偏好的結構性變化奠定了基礎。

基因組工程、PDX技術以及整合服務交付的進步如何重新定義轉化價值和實驗可重複性

由於技術、操作和科學力量的融合，人源化囓齒動物模型領域正在經歷顯著的變化。首先，精準的基因組工程和先進的免疫移植方法提高了人源化免疫系統和器官特異性表現型的保真度，從而能夠更有效地評估免疫療法和生技藥品的療效。同時，患者來源的異質骨移植模型庫的廣泛應用以及冷凍保存技術的改進，有助於保持腫瘤的異質性和臨床相關性，從而加速轉化腫瘤學計畫的進展。

同時，業界正朝著模組化服務模式發展，將模型交付、效能測試和篩檢服務整合在一起，以簡化申辦方的工作流程並減少行政障礙。監管的加強和對可重複性的日益成長的期望，促使企業採用更嚴格的文件記錄、標準化的終點指標和第三方品質審核。此外，將體內數據與多組體學讀數和高級分析進行計算整合，正逐漸成為機制闡明和研究設計最佳化的核心競爭力。總而言之，這些轉變正在促進一個更協作的生態系統的發展，在這個生態系統中，多學科夥伴關係、垂直整合和基於平台的方法定義了競爭優勢和科學價值。

評估2025年關稅調整如何影響臨床前研究生態系統的供應韌性、籌資策略和供應商多元化。

2025年前後實施的累積政策調整和關稅措施對依賴專業動物模型和持續實驗室投入的機構的供應鏈和營運規劃產生了多方面的影響。對許多終端使用者而言，最直接的影響是進口種畜、專用耗材和某些試劑的到岸成本增加，促使採購團隊重新談判供應商合約、合併訂單，並優先選擇製造地分佈在各地的供應商。作為應對措施，一些供應商採取了相應措施，包括轉移關鍵生產過程、盡可能提高國內產能以及擴大本地庫存以適應更長的前置作業時間。

除了直接的成本影響外，關稅也在影響籌資策略和供應商選擇決策，凸顯了合約彈性和透明的前置作業時間承諾的重要性。在某些情況下，跨境物流變得更加難以預測，促使申辦方加快採用替代模式和供應商檢驗計劃，以確保實驗按時完成。此外，貿易政策的調整增加了合規要求和文件負擔，迫使實驗室和採購團隊加強海關專業知識和風險管理實踐。總而言之，這些動態正在推動供應鏈網路朝向更具韌性的方向發展，更加重視供應商資格確認，並增加對冗餘系統的策略性投資，以保障關鍵的臨床前工作流程。

深度細分智慧揭示了模型類型、應用重點、最終用戶優先級以及產品服務組合如何驅動採購和研發選擇。

按模型類型、應用、最終用戶和產品類型分析人源化囓齒動物模型市場，揭示了其對研發規劃者和採購負責人的策略意義。按模型類型分類，該市場包括人源化大鼠模型、免疫力缺乏模型、PDX模型和基因轉殖模型。人源化大鼠模型包括hACE2大鼠模型和hCD4大鼠模型，它們分別與病毒嗜性和免疫腫瘤學研究密切相關。其他免疫力缺乏模型包括NOG、NSG和SCID模型，這些模型在移植效率、免疫表現型以及與各種異種移植和人體免疫系統重建流程的兼容性方面各不相同。患者來源的異種移植模型涵蓋乳癌、結腸癌和肺癌PDX模型，提供疾病特異性的保真度，以支持治療假設檢驗和生物標記發現。用於機制闡明和標靶檢驗的基因改造模型包括基因敲入模型和基因敲除模型，每種模型在研究基因功能和路徑調控方面都具有獨特的優勢。

根據應用領域，我們的產品組合滿足心血管、免疫學、感染疾病、神經病學和腫瘤學的研究需求。循環系統應用包括支持藥物安全性和機制研究的動脈粥狀硬化和高血壓模型；免疫系統應用包括對生技藥品開發至關重要的自體免疫和發炎性疾病模型。感染疾病應用分為細菌感染模型和病毒感染模型，此區分指南根據宿主易感性和生物安全性進行選擇。神經病學應用包括有助於開發中樞神經系統標靶治療方法的神經退化性疾病和疼痛模型。腫瘤學應用根據腫瘤微環境的考量分為血液腫瘤模型和固態腫瘤模型。最終用戶分為學術研究機構、受託研究機構、製藥公司和生技公司，每家機構的採購時間、檢驗閾值和服務偏好各不相同。最後，產品類型包括模型產品和服務。模型產品細分為市售模型和客製化模型，以滿足現成產品和客製化開發的需求。另一方面，服務包括療效測試服務、模型開發服務以及支援研究實施和轉化驗證的篩檢服務。

綜合以上幾個方面，我們發現模型選擇決策越來越受到生物學保真度、服務整合和操作確定性等因素的共同驅動。專注於免疫療法的申辦者通常傾向於選擇特徵明確的免疫力缺乏細胞系和客製化的人源化構建體，而腫瘤團隊則往往優先考慮能夠保留腫瘤異質性的PDX模型。同時，製藥和生技公司重視符合GLP規範的供應商、可重複的供應鏈以及承包服務包。服務差異化，尤其是在模型開發和療效測試方面，是關鍵的競爭優勢，能夠幫助供應商建立長期夥伴關係，並減少複雜專案中的交易摩擦。

區域對比分析詳細闡述了美洲、歐洲、中東和非洲以及亞太地區各自的優勢如何影響模式採購、合規和服務採用。

區域動態對供給側能力、調節互動以及人源化囓齒動物模型的應用軌跡產生不同的影響。在美洲，生物中心的集中、強大的轉化研發管線以及成熟的合約研究產業，為先進人源化構建體和PDX平台的廣泛應用提供了有力支撐。該地區擁有完善的研究設施基礎設施和強大的服務供應商網路，降低了複雜體內實驗項目的進入門檻。相較之下，歐洲、中東和非洲地區（EMEA）的情況則較為複雜，學術中心和專業服務提供者的優勢領域與不同的法規結構和報銷環境並存。這種多樣性為跨境合作和專業化細分服務創造了機遇，但也要求各方謹慎應對動物福利標準和進出口法規的差異。

亞太地區在育種設施、合約研究組織（CRO）服務和轉化研究中心方面正經歷著快速的產能擴張，同時，本土開發的模式生物品系數量不斷增加，並日益重視本地試劑生產。因此，該地區為開展大規模臨床前計畫的相關人員提供了具有競爭力的價格和規模優勢。在所有地區，物流因素、海關流程和區域政策變更都會影響前置作業時間和供應商選擇。因此，跨國計畫通常採用混合籌資策略，將本地能力用於常規測試，並與國際合作夥伴合作開發高度專業或檢驗的模式生物系統。

供應商策略、服務整合、專有模型開發和夥伴關係等方面的競爭考察，這些因素共同決定了臨床前測試服務的競爭優勢。

供應商和服務供應商之間的競爭動態呈現出專業化和整合並存的特點，各公司都在追求垂直整合、專有模型庫和增值服務組合。領先的服務供應商正在增加對冷凍保存的PDX庫、先進的表現型分析平台和專有的人源化方案的投資，以確保與客戶建立長期的合作關係並實現技術差異化。同時，委外研發機構（ CRO）正透過策略聯盟、產能投資以及增建符合GLP規範的設施來擴展其體內研究能力，以支持後期治療計畫。

技術創新主要集中在提高移植效率、降低異質骨移植變異性以及擴展基因轉移構建體的種類，以應對特定的機制問題。在品質系統、可追溯性和監管文件方面表現卓越的供應商，在與大型製藥公司合作時具有競爭優勢，因為這些公司對供應商資格要求非常嚴格。此外，整合模型開發、療效測試和生物標記檢測的服務模式，能夠幫助供應商提升價值鏈，並獲得更高的贊助商支出佔有率。最後，與學術中心和醫院網路的合作日益普遍，這有助於獲取用於構建PDX模型的新鮮腫瘤檢體，並促進轉化醫學合作，從而加速目標檢驗和臨床轉化。

領導者可以採取哪些切實可行的策略步驟來增強供應商的韌性、轉化相關性、監管反應能力和服務整合能力？

產業領導者可以採取一系列切實可行的措施，增強其在不斷發展的人源化囓齒動物生態系統中的營運韌性、科學嚴謹性和商業性地位。首先，應優先考慮供應商資質資格確認流程，包括記錄繁殖記錄、基因檢驗和移植性能，並將這些標準納入長期採購契約，以減少差異。其次，應投資關鍵模型和試劑的雙重籌資策略和區域冗餘，以減輕政策變化和物流限制帶來的干擾，並確保研究按時完成。

第三，我們將發展內部轉化檢測開發和數據整合能力，從而更便捷地將體內研究結果與多組體學和影像學讀數整合，以提升臨床前項目的預測價值。第四，我們將與CRO合作夥伴協商服務水準承諾，包括明確的時間表、緊急應變計畫和雙方共同的績效指標，以協調獎勵並減少後續延誤。第五，我們將加快在各項研究中採用標準化報告格式和元資料框架，以提高研究結果的可重複性並促進與監管機構的溝通。第六，我們將尋求與臨床中心和生物樣本庫的策略合作，以擴大PDX（患者來源異種移植模型）的獲取途徑，並提高轉化相關性。第七，我們將投入資源，持續進行員工在動物福利、生物安全和法規遵從方面的培訓，以確保研究的倫理性和高品質。最後，我們將評估我們專有模型和平台服務的商業化機會，在許可潛力與規模化和品質保證的營運需求之間取得平衡。

我們採用透明、三角驗證的研究途徑，結合專家訪談、文件分析和檢驗檢查，為相關人員提供可靠的策略見解。

本分析的調查方法結合了結構化的初步研究、嚴謹的二手資料審查和迭代檢驗，以確保研究結果的可靠性和可操作性。初步研究包括對科學研究負責人、採購經理和合約研究組織（CRO）高階主管的訪談，以了解實際決策標準、前置作業時間敏感性以及不斷變化的服務期望。二手資料審查涵蓋了同行評審文獻、監管指導文件、產品技術文獻和營運報告，以梳理技術發展軌跡和品質標準。這些定性資訊和文獻資料被整合起來，用於建構市場細分框架、供應鏈影響情境分析和區域比較評估。

為確保結論的有效性，我們採用了三角驗證法，將訪談內容與供應商文獻和營運績效指標進行交叉比對，並進行了後續諮詢以解決任何差異。品管程序包括標準化的訪談指南、資訊來源歸屬記錄以及記錄關鍵假設的可重複性檢查清單。我們認知到，我們的方法受限於供應商特定數據和快速變化的政策環境。因此，我們建議讀者將我們的研究結果視為策略指導，在製定採購和研發決策時，應結合公司本身的實質審查。

最後總結指出，整合科學嚴謹性、供應商合格和營運彈性對於轉換成功至關重要。

總之，人源化小鼠和大鼠模型是實驗生物學與臨床應用之間的關鍵紐帶，在基因工程、PDX保存和整合服務交付等領域的持續創新推動下，它們正在重新定義臨床前策略。技術進步、監管預期和供應鏈動態之間的相互作用，迫使申辦方採用更精細的採購、資格確認和合作方式。隨著關稅和政策環境的演變，那些投資於供應商多元化、嚴謹的文件記錄和轉化檢測整合的機構，將更有利於保持專案進展勢頭，並從體內試驗中獲得更高的預測價值。

最終，競爭格局將青睞那些兼具卓越科學水準和嚴謹營運能力的公司。那些能夠提供高度可重複、特徵明確的模型以及承包服務的公司，將能夠加深與申辦者的合作，並支持其快速決策。透過應用本文提出的細分洞察、區域考量和可操作建議，相關人員可以將他們的臨床前策略與科學重點和營運實際情況相結合，從而加速治療藥物的研發並降低風險。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • CRISPR/Cas9修飾的人源化小鼠模型的廣泛應用提高了免疫腫瘤學研究的可重複性。
  • 在臨床前研究中，對人源化大鼠模型的需求不斷成長，以改善藥物動力學和毒性分析。
  • 整合多組體學和人源化囓齒動物模型，加速個人化醫療和生物標記發現
  • 生技公司與學術機構合作開發下一代人源化囓齒動物平台
  • 新興市場對人源化動物模型服務的需求成長，主要受生技藥品研發管線投資增加的推動。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依模型類型分類的人源化小鼠和大鼠模型市場

  • 人源化大鼠模型
    • hACE2 大鼠模型
    • hCD4 大鼠模型
  • 免疫力缺乏模型
    • NOG模型
    • NSG模型
    • SCID模型
  • PDX 型號
    • 乳癌PDX
    • 大腸直腸癌PDX
    • 肺癌PDX
  • 基因改造模型
    • 敲入式模型
    • 淘汰賽模特兒

9. 按應用分類的人源化小鼠和大鼠模型市場

  • 心血管系統
    • 動脈硬化模型
    • 高血壓模型
  • 免疫學
    • 自體免疫疾病模型
    • 發炎性疾病模型
  • 感染疾病
    • 細菌感染模型
    • 病毒感染模型
  • 神經病學
    • 神經退化性疾病模型
    • 疼痛模型
  • 腫瘤學
    • 血液學模型
    • 固態腫瘤模型

第10章 人源化小鼠和大鼠模型市場（依最終用戶分類）

  • 學術研究機構
  • 受託研究機構
  • 製藥和生物技術公司

第11章 人源化小鼠和大鼠模型市場（依產品類型分類）

  • 模型產品
    • 商業模式
    • 客製化模型
  • 服務
    • 功效測試服務
    • 模型開發服務
    • 篩檢服務

12. 各地區人源化小鼠與大鼠模型市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 人源化小鼠和大鼠模型市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國人源化小鼠與大鼠模型市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Charles River Laboratories International, Inc.
    • The Jackson Laboratory, Inc.
    • Taconic Biosciences, Inc.
    • Inotiv, Inc.
    • PerkinElmer, Inc.
    • Crown Bioscience International, Inc.
    • Biocytogen Pharmaceuticals Ltd.
    • BioIVT, Inc.
    • Cyagen Biosciences Inc.
    • GemPharmatech Co., Ltd.
Product Code: MRR-961BA04A2E3A

The Humanized Mouse & Rat Model Market is projected to grow by USD 494.48 million at a CAGR of 7.56% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 275.91 million
Estimated Year [2025] USD 297.24 million
Forecast Year [2032] USD 494.48 million
CAGR (%) 7.56%

An expert overview of how humanized mouse and rat model innovations are reshaping preclinical pipelines and translational research priorities

Humanized mouse and rat models have emerged as indispensable tools in contemporary preclinical research, enabling translational insights across immunology, infectious disease, oncology, neurology, and cardiovascular science. These engineered and patient-derived systems increasingly bridge the chasm between in vitro findings and clinical reality by providing physiologically relevant contexts in which human-specific immune interactions, pathogen tropisms, and tumor biology can be interrogated. As experimental objectives have become more complex, investigators and product developers have demanded higher fidelity models, robust characterization, and integrated service offerings that reduce time to actionable data and enhance reproducibility.

Consequently, suppliers, contract research providers, and academic consortia have expanded their portfolios to include advanced humanized rat variants, a broader range of immunodeficient strains, patient-derived xenograft collections, and precise transgenic constructs. At the same time, improvements in genome editing, breeding, and husbandry, together with enhanced phenotyping and bioassay capabilities, have reshaped how sponsors design preclinical programs. This introduction sets the stage for a deeper analysis of the structural shifts influencing model selection, sourcing strategies, regulatory touchpoints, and end-user preferences, while emphasizing the operational complexities and scientific opportunities that characterize the current landscape.

How advancements in genome engineering, PDX capabilities, and integrated service delivery are redefining translational value and experimental reproducibility

The landscape for humanized rodent models is undergoing transformative shifts driven by converging technological, operational, and scientific forces. First, precision genome engineering and refined immunoengraftment methods have increased the fidelity of humanized immune systems and organ-specific phenotypes, enabling more predictive assessments of immunotherapies and biologics. At the same time, the proliferation of patient-derived xenograft collections and improved cryopreservation practices have accelerated translational oncology programs by preserving tumor heterogeneity and clinical relevance.

Meanwhile, the industry is experiencing a move toward modular service delivery where model provision, efficacy testing, and screening services are bundled to streamline sponsor workflows and reduce administrative friction. Regulatory scrutiny and heightened reproducibility expectations have spurred more rigorous documentation, standardized endpoints, and third-party quality audits. In parallel, computational integration-combining in vivo data with multi-omic readouts and advanced analytics-has emerged as a core capability for unlocking mechanistic insight and optimizing study design. Collectively, these shifts are fostering a more collaborative ecosystem in which cross-disciplinary partnerships, vertical integration, and platform-based approaches define competitive advantage and scientific value.

Assessing how 2025 tariff adjustments shaped supply resilience, procurement strategies, and vendor diversification in preclinical research ecosystems

The cumulative policy adjustments and tariff measures enacted in and around 2025 have exerted a multifaceted impact on supply chains and operational planning for organizations that rely on specialized animal models and contiguous laboratory inputs. For many end users, the immediate effect has been an increase in landed costs for imported breeding stock, specialized consumables, and certain reagents, which has prompted procurement teams to renegotiate supplier agreements, consolidate orders, and prioritize vendors with geographically diversified manufacturing footprints. In response, several providers have adapted by relocating critical production steps, increasing domestic breeding capacity where feasible, and expanding local inventories to buffer against longer lead times.

Beyond direct cost effects, tariffs have influenced decisions about sourcing strategy and vendor selection, reinforcing the importance of contractual flexibility and transparent lead-time commitments. In cases where cross-border logistics became less predictable, sponsors accelerated validation programs for alternative models and suppliers to preserve experimental timelines. Moreover, adjustments in trade policy have elevated compliance requirements and documentation burdens, obliging laboratory and procurement teams to strengthen customs expertise and risk management practices. Taken together, these dynamics have encouraged a shift toward more resilient supply networks, greater emphasis on supplier qualification, and strategic investments in redundancy to protect critical preclinical workflows.

Deep segmentation intelligence revealing how model type, application focus, end-user priorities, and product-service configurations drive procurement and R&D choices

Disaggregating the humanized rodent landscape by model type, application, end user, and product typology reveals targeted strategic implications for R&D planners and procurement leaders. When examined by model type, the market encompasses humanized rat models, immunodeficient models, PDX models, and transgenic models. The humanized rat models category includes hACE2 rat models and hCD4 rat models, which are particularly relevant for viral tropism studies and immuno-oncology investigations respectively. Immunodeficient models further comprise NOG models, NSG models, and SCID models, with variation in engraftment efficiency, immunophenotype, and suitability for diverse xenograft and human immune system reconstitution workflows. Patient-derived xenograft models span breast cancer PDX, colorectal cancer PDX, and lung cancer PDX, offering disease-specific fidelity that supports therapeutic hypothesis testing and biomarker discovery. Transgenic models that are leveraged for mechanistic interrogation and target validation include both knock-in models and knock-out models, each providing distinct advantages for studying gene function and pathway modulation.

Viewed by application, the portfolio aligns with cardiovascular, immunology, infectious disease, neurology, and oncology research needs. Cardiovascular applications include atherosclerosis models and hypertension models that support drug safety and mechanism studies, while immunology applications cover autoimmune disorder models and inflammatory disease models that are critical to biologics development. Infectious disease applications are differentiated into bacterial infection models and viral infection models, a distinction that guides choices around host susceptibility and biosafety. Neurology applications include neurodegenerative disease models and pain models that help translate CNS-targeted therapies, and oncology applications divide into hematological models and solid tumor models depending on tumor microenvironment considerations. End users are typified by academic research institutes, contract research organizations, and pharmaceutical and biotech companies, each adopting different procurement timelines, validation thresholds, and service preferences. Finally, product type distinctions comprise model products and services. Model products are subdivided into commercial models and custom models that address off-the-shelf versus bespoke needs, while services include efficacy testing services, model development services, and screening services that support study execution and translational validation.

Taken together, these segment dimensions indicate that decisions around model selection are increasingly driven by a combination of biological fidelity, service integration, and operational certainty. Sponsors focused on immunotherapies often favor highly characterized immunodeficient strains and tailored humanized constructs, while oncology teams frequently prioritize PDX collections that preserve tumor heterogeneity. Academic institutes are more likely to adopt open-source or academic-sourced models for exploratory work, whereas pharmaceutical and biotech companies emphasize GLP-compliant vendors, reproducible supply chains, and turnkey service packages. Service differentiation-particularly in model development and efficacy testing-has become a principal competitive lever, enabling suppliers to capture longer-term partnerships and reduce transactional friction for complex programs.

Comparative regional analysis detailing how Americas, Europe, Middle East & Africa, and Asia-Pacific differential strengths influence model sourcing, compliance, and service adoption

Regional dynamics shape supply-side capabilities, regulatory interactions, and adoption trajectories for humanized rodent models in distinct ways. In the Americas, a concentration of biotech hubs, strong translational pipelines, and a mature contract research sector support high adoption of advanced humanized constructs and PDX platforms. This region benefits from considerable laboratory infrastructure and a robust service-provider network, which collectively lower barriers to entry for complex in vivo programs, but also face cost pressures related to labor and regulatory compliance. In contrast, Europe, Middle East & Africa displays a heterogeneous landscape where pockets of excellence in academic centers and specialized providers coexist with varied regulatory frameworks and reimbursement environments. This diversity yields opportunities for cross-border collaborations and specialized niche services, yet it also requires careful navigation of differing animal welfare standards and import/export regulations.

The Asia-Pacific region has seen rapid capacity expansion in breeding facilities, CRO services, and translational research hubs, coupled with an increasing number of domestically developed model lines and a growing emphasis on local manufacturing of reagents. As a result, this region offers competitive pricing and scale advantages for sponsors pursuing large preclinical programs, though stakeholders should assess supplier quality systems and documentation to ensure alignment with global regulatory expectations. Across all regions, logistical factors, customs processes, and regional policy shifts influence lead times and supplier selection. Consequently, multinational programs often adopt hybrid sourcing strategies that combine local capacity for routine studies with international partners for highly specialized or validated model systems.

Insights into supplier strategies, service integration, proprietary model development, and partnerships that define competitive advantage in preclinical services

Competitive dynamics among suppliers and service providers are characterized by a mix of specialization and consolidation, as firms pursue vertical integration, proprietary model libraries, and value-added service bundles. Leading providers increasingly invest in cryopreserved PDX banks, advanced phenotyping platforms, and proprietary humanization protocols to secure durable client relationships and create technical differentiation. Parallel to this, contract research organizations are expanding their in vivo capabilities through strategic alliances, capacity investments, and the addition of GLP-compliant facilities to support late-stage therapeutic programs.

Innovation is concentrated around improving engraftment efficiency, reducing xenograft variability, and expanding the repertoire of transgenic constructs tailored to specific mechanistic questions. Providers that excel in quality systems, traceability, and regulatory documentation have a competitive advantage when engaging with large pharmaceutical sponsors who require stringent supplier qualification. In addition, service models that integrate model development, efficacy testing, and biomarker readouts enable suppliers to move up the value chain and capture a greater share of sponsor spend. Finally, partnerships with academic centers and hospital networks are becoming more common, facilitating access to fresh tumor specimens for PDX generation and enabling translational collaborations that accelerate target validation and clinical translation.

Actionable strategic steps leaders should implement to enhance supplier resilience, translational validity, regulatory readiness, and service integration

Industry leaders can adopt a set of pragmatic actions to strengthen operational resilience, scientific rigor, and commercial positioning in the evolving humanized rodent ecosystem. First, prioritize supplier qualification processes that include documentation of breeding records, genetic validation, and engraftment performance, and integrate those criteria into long-term procurement agreements to reduce variability. Second, invest in dual-sourcing strategies and regional redundancy for critical models and reagents in order to mitigate disruptions from policy shifts or logistics constraints, thereby preserving study timelines.

Third, foster internal capabilities for translational assay development and data harmonization so that in vivo findings can be more readily integrated with multi-omic and imaging readouts, increasing the predictive value of preclinical programs. Fourth, negotiate service-level commitments with CRO partners that include clearly defined timelines, contingency plans, and mutual performance metrics to align incentives and reduce downstream delays. Fifth, accelerate the adoption of standardized reporting formats and metadata frameworks across studies to enhance reproducibility and facilitate regulatory engagement. Sixth, pursue strategic collaborations with clinical centers and biobanks to expand access to diverse PDX sources and to enrich translational relevance. Seventh, allocate resources to continuous staff training on animal welfare, biosafety, and regulatory compliance to ensure ethical and high-quality study conduct. Finally, evaluate commercialization opportunities for proprietary models and platform services, balancing licensing potential with the operational demands of scale and quality assurance.

A transparent, triangulated research approach combining expert interviews, documentary analysis, and validation checks to produce reliable strategic insights for stakeholders

The research methodology underpinning this analysis combined structured primary inquiry, rigorous secondary review, and iterative validation to ensure the findings are robust and actionable. Primary inputs included interviews with scientific leaders, procurement managers, and CRO executives to capture real-world decision criteria, lead-time sensitivities, and evolving service expectations. Secondary review encompassed peer-reviewed literature, regulatory guidance documents, technical product literature, and operational reports to map technological trajectories and quality standards. These qualitative and documentary inputs were synthesized to develop a segmentation framework, scenario analyses for supply-chain impacts, and comparative regional assessments.

To validate conclusions, triangulation was employed through cross-referencing interview insights with supplier literature and operational performance indicators, and follow-up consultations were conducted to reconcile divergent perspectives. Quality control procedures included standardized interview guides, source attribution logs, and a reproducibility checklist that documented key assumptions. The methodology acknowledges limitations tied to proprietary supplier data and the rapidly changing policy environment; as such, readers are encouraged to treat the insights as strategic guidance that should be augmented with firm-specific due diligence when making procurement or R&D decisions.

Final synthesis emphasizing why integration of scientific fidelity, supplier qualification, and operational resilience is essential for translational success

In conclusion, humanized mouse and rat models represent a vital nexus between experimental biology and clinical translation, with ongoing innovations in genetic engineering, PDX preservation, and integrated service delivery redefining preclinical strategy. The interplay of technological progress, regulatory expectations, and supply-chain dynamics requires sponsors to adopt more sophisticated procurement, qualification, and collaboration practices. As tariff and policy environments evolve, organizations that invest in supplier diversification, rigorous documentation, and translational assay integration will be better positioned to sustain program momentum and extract higher predictive value from in vivo studies.

Ultimately, the competitive landscape rewards those who combine scientific excellence with operational discipline: firms that can deliver reproducible, well-characterized models alongside turnkey services will capture deeper sponsor engagement and support faster decision making. By applying the segmentation insights, regional considerations, and actionable recommendations provided herein, stakeholders can align their preclinical strategies with scientific priorities and operational realities to accelerate therapeutic development and mitigate risk.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Surge in CRISPR/Cas9 engineered humanized mouse models enhancing immuno-oncology research reproducibility
  • 5.2. Rising demand for humanized rat models to improve pharmacokinetic and toxicity profiling in preclinical studies
  • 5.3. Integration of multi-omics and humanized rodent models to accelerate personalized medicine and biomarker discovery
  • 5.4. Collaboration between biotech firms and academic institutions to develop next generation humanized rodent platforms
  • 5.5. Expansion of humanized animal model services in emerging markets driven by growing biologics pipeline investments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Humanized Mouse & Rat Model Market, by Model Type

  • 8.1. Humanized Rat Models
    • 8.1.1. hACE2 Rat Models
    • 8.1.2. hCD4 Rat Models
  • 8.2. Immunodeficient Models
    • 8.2.1. NOG Models
    • 8.2.2. NSG Models
    • 8.2.3. SCID Models
  • 8.3. PDX Models
    • 8.3.1. Breast Cancer PDX
    • 8.3.2. Colorectal Cancer PDX
    • 8.3.3. Lung Cancer PDX
  • 8.4. Transgenic Models
    • 8.4.1. Knock-In Models
    • 8.4.2. Knock-Out Models

9. Humanized Mouse & Rat Model Market, by Application

  • 9.1. Cardiovascular
    • 9.1.1. Atherosclerosis Models
    • 9.1.2. Hypertension Models
  • 9.2. Immunology
    • 9.2.1. Autoimmune Disorder Models
    • 9.2.2. Inflammatory Disease Models
  • 9.3. Infectious Disease
    • 9.3.1. Bacterial Infection Models
    • 9.3.2. Viral Infection Models
  • 9.4. Neurology
    • 9.4.1. Neurodegenerative Disease Models
    • 9.4.2. Pain Models
  • 9.5. Oncology
    • 9.5.1. Hematological Models
    • 9.5.2. Solid Tumor Models

10. Humanized Mouse & Rat Model Market, by End User

  • 10.1. Academic Research Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Pharmaceutical Biotech Companies

11. Humanized Mouse & Rat Model Market, by Product Type

  • 11.1. Model Products
    • 11.1.1. Commercial Models
    • 11.1.2. Custom Models
  • 11.2. Services
    • 11.2.1. Efficacy Testing Services
    • 11.2.2. Model Development Services
    • 11.2.3. Screening Services

12. Humanized Mouse & Rat Model Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Humanized Mouse & Rat Model Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Humanized Mouse & Rat Model Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Charles River Laboratories International, Inc.
    • 15.3.2. The Jackson Laboratory, Inc.
    • 15.3.3. Taconic Biosciences, Inc.
    • 15.3.4. Inotiv, Inc.
    • 15.3.5. PerkinElmer, Inc.
    • 15.3.6. Crown Bioscience International, Inc.
    • 15.3.7. Biocytogen Pharmaceuticals Ltd.
    • 15.3.8. BioIVT, Inc.
    • 15.3.9. Cyagen Biosciences Inc.
    • 15.3.10. GemPharmatech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HUMANIZED MOUSE & RAT MODEL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HUMANIZED MOUSE & RAT MODEL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HUMANIZED MOUSE & RAT MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEURODEGENERATIVE DISEASE MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEURODEGENERATIVE DISEASE MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEURODEGENERATIVE DISEASE MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEURODEGENERATIVE DISEASE MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEURODEGENERATIVE DISEASE MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEURODEGENERATIVE DISEASE MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PAIN MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PAIN MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PAIN MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PAIN MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PAIN MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PAIN MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HEMATOLOGICAL MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HEMATOLOGICAL MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HEMATOLOGICAL MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HEMATOLOGICAL MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HEMATOLOGICAL MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HEMATOLOGICAL MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SOLID TUMOR MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SOLID TUMOR MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SOLID TUMOR MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SOLID TUMOR MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SOLID TUMOR MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SOLID TUMOR MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COMMERCIAL MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COMMERCIAL MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COMMERCIAL MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COMMERCIAL MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COMMERCIAL MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COMMERCIAL MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CUSTOM MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CUSTOM MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CUSTOM MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CUSTOM MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CUSTOM MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CUSTOM MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY EFFICACY TESTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY EFFICACY TESTING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY EFFICACY TESTING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY EFFICACY TESTING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY EFFICACY TESTING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY EFFICACY TESTING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL DEVELOPMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL DEVELOPMENT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL DEVELOPMENT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL DEVELOPMENT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL DEVELOPMENT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL DEVELOPMENT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCREENING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCREENING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCREENING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCREENING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCREENING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCREENING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE,